Zydus Lifesciences Ltd Upgraded to Buy on Strong Technical and Fundamental Signals

Technical Momentum Shifts to Bullish

The primary catalyst for the rating upgrade is the significant improvement in Zydus Lifesciences’ technical profile. The technical trend has shifted from mildly bullish to outright bullish, signalling stronger market confidence. Key technical indicators present a mixed but overall positive picture. On a weekly basis, the MACD remains mildly bearish, but the monthly MACD has turned bullish, indicating longer-term upward momentum. The Relative Strength Index (RSI) shows no immediate signal on both weekly and monthly charts, suggesting the stock is not overbought or oversold.

Bollinger Bands have turned bullish on both weekly and monthly timeframes, reflecting increased price volatility in an upward direction. Daily moving averages confirm a bullish stance, reinforcing short-term strength. The Know Sure Thing (KST) indicator is mildly bearish weekly but bullish monthly, while Dow Theory readings are mildly bearish weekly and mildly bullish monthly. On-balance volume (OBV) shows no trend weekly but is bullish monthly, indicating accumulation over the longer term.

These technical signals collectively suggest that while short-term fluctuations remain, the medium to long-term outlook is positive, supporting the upgrade in the technical grade and overall Mojo Score to 71.0.

Quality Assessment: Strong Long-Term Fundamentals

Zydus Lifesciences maintains a strong quality profile, reflected in its low debt levels and consistent profitability. The company’s average debt-to-equity ratio stands at a minimal 0.05 times, underscoring a conservative capital structure that reduces financial risk. Return on Equity (ROE) averages 17.49%, signalling efficient utilisation of shareholders’ funds to generate profits. Additionally, the Return on Capital Employed (ROCE) is an attractive 21.8%, indicating effective deployment of capital in operations.

Net sales have grown at a compound annual growth rate (CAGR) of 13.79%, while operating profit has expanded at an even stronger 19.95% annually. These figures highlight the company’s ability to sustain healthy growth and operational efficiency over the long term. Despite a recent negative quarterly performance, the underlying fundamentals remain robust, justifying the Buy rating upgrade.

Valuation: Fairly Priced with Attractive Metrics

From a valuation standpoint, Zydus Lifesciences is trading at a reasonable level relative to its peers and historical averages. The company’s Enterprise Value to Capital Employed (EV/CE) ratio is 3.6, which is considered attractive for a mid-cap pharmaceutical firm with strong growth prospects. The stock price of ₹1,130.00 is below its 52-week high of ₹1,205.65 but comfortably above the 52-week low of ₹835.85, indicating a stable price range.

The Price/Earnings to Growth (PEG) ratio stands at 4.5, reflecting moderate expectations for future earnings growth relative to the current price. While this PEG ratio suggests some premium, it is supported by the company’s consistent long-term growth and profitability. Over the past year, the stock has delivered a 10.42% return, outperforming the BSE500 index and demonstrating market confidence in its valuation.

Financial Trend: Recent Challenges Amidst Long-Term Strength

Despite the positive upgrade, Zydus Lifesciences reported a negative financial performance in Q1 FY26-27, which warrants cautious attention. The company’s Profit Before Tax excluding Other Income (PBT less OI) declined by 30.98% to ₹1,218.70 crores, while Profit After Tax (PAT) fell by 35.0% to ₹953.07 crores. Interest expenses for the nine months increased sharply by 55.71% to ₹408.90 crores, indicating rising financing costs.

These quarterly setbacks contrast with the company’s otherwise healthy long-term financial trajectory. Net sales and operating profits have shown steady growth, and the company’s low leverage mitigates the impact of increased interest expenses. Investors should monitor upcoming quarterly results to assess whether these headwinds are temporary or indicative of a broader trend.

Market Performance: Outperforming Benchmarks

Zydus Lifesciences has demonstrated strong market-beating returns over multiple time horizons. Year-to-date, the stock has surged 23.54%, significantly outperforming the Sensex’s negative 8.88% return. Over one year, the stock gained 10.42% compared to the Sensex’s decline of 4.88%. Longer-term returns are even more impressive, with a three-year gain of 79.71% versus the Sensex’s 19.68%, and a five-year return of 108.16% compared to 38.81% for the benchmark.

This consistent outperformance highlights the company’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector. The stock’s current momentum is supported by both fundamental strength and improving technical indicators, reinforcing the rationale for the upgrade to a Buy rating.

Sector and Market Context

Zydus Lifesciences operates within the Pharmaceuticals & Biotechnology sector, a space characterised by steady demand and innovation-driven growth. The company is classified as a mid-cap stock with a market capitalisation grade reflecting its size and market presence. It is among the top 1% of companies rated by MarketsMojo across over 4,000 stocks, underscoring its quality and market standing.

Its majority shareholders are promoters, providing stable ownership and strategic direction. The company’s stock price has shown resilience, with a day change of 2.63% on 26 August 2026, closing at ₹1,130.00. This price movement aligns with the improved technical outlook and positive investor sentiment.

Risks and Considerations

Investors should remain mindful of the recent negative quarterly results, which highlight potential near-term challenges. The sharp rise in interest expenses and decline in profitability metrics could pressure margins if sustained. Additionally, the PEG ratio of 4.5 suggests that the stock is priced for growth, which may limit upside if earnings disappoint.

However, the company’s strong balance sheet, low debt, and long-term growth trajectory provide a buffer against these risks. The upgrade to a Buy rating reflects a balanced view that acknowledges short-term volatility while favouring the company’s fundamental and technical strengths.

Conclusion

MarketsMojo’s upgrade of Zydus Lifesciences Ltd from Hold to Buy is driven by a confluence of improved technical indicators, attractive valuation, solid financial trends, and high-quality fundamentals. Despite recent quarterly setbacks, the company’s long-term growth, low leverage, and market-beating returns support a positive investment stance. The technical trend’s shift to bullish, combined with strong profitability metrics such as ROE of 17.49% and ROCE of 21.8%, underpin the confidence in the stock’s future performance.

Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find Zydus Lifesciences an appealing candidate, given its mid-cap status, stable promoter ownership, and consistent market outperformance. Monitoring upcoming quarterly results will be crucial to validate the sustainability of the current momentum and financial health.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today